Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBIENCE trial of zenagamtide for major cardiovascular risk reduction in adults with established atherosclerotic cardiovascular disease and overweight or obesity
MOH_2026-07-28_016957Phase 3Not yet recruiting
- Sponsor
- Novo Nordisk
- Start
- Jul 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in atherosclerotic disease, Overweight and obesity comparing zenagamtide with placebo (2 arms). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
amycretin
03
Conditions
atherosclerotic diseaseOverweightobesity
Beyond the preview
Go deeper on MOH_2026-07-28_016957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-07-28_016957.